Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:16 PM
Ignite Modification Date:
2025-12-24 @ 7:16 PM
NCT ID:
NCT06587503
Eligibility Criteria:
Inclusion Criteria:
* Healthy male and female adults between ages 18-50 years, who are able and willing to provide written informed consent and will comply with the study requirements.
* Already completed a primary course of COVID-19 immunisation (any World Health Organisation approved primary immunisation course is acceptable).
Exclusion Criteria:
* Unwilling or unable to provide written informed consent to take part
* Unwilling or unable to comply with study procedures
* Previously received an Ebola vaccine or previous exposure to Ebola virus (including serological and clinical diagnoses, irrespective of viral strain)
* Not received a primary course of COVID-19 immunisation
* History of any suspected or confirmed disorder of the immune system that, in the opinion of the Investigators, might impair the results of the study
* Use of immunosuppressant medication within the past 6 months (excluding topical steroids or oral steroid courses lasting \<7 days)
* Current diagnosis or treatment of cancer (unless non-melanomatous skin cancer)
* Have a bleeding disorder deemed significant by study doctor
* Pregnant or breast-feeding females
* Able to avoid close contact with vulnerable individuals, including via high-risk blood and bodily fluids for 6 weeks following vaccination to reduce the risk of transmission to vulnerable individuals (e.g. immuno-compromised individuals, individuals receiving immunosuppressive therapy, pregnant or breast-feeding women, children \<1 year of age).
* Unable to prevent contact of their blood or bodily fluids with farm animals in the 6 weeks following vaccination
* Plan to donate blood in the 6 weeks following vaccination
* Hypersensitivity to any active substances, excipients, or rice protein.
* History of anaphylaxis to any component of vaccine formulation.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT06587503
Study Brief:
Protocol Section:
NCT06587503